Name: Forget Injections. Now You Can Just Take Pills For Weight Loss
Uploaded: 2026-01-15T21:01:30.000Z
Duration: 2 min 58 s
Description: Thousands of YouTube videos with English-Chinese subtitles! Now you can learn to understand native speakers, expand your vocabulary, and improve your pronunciation...

The GLP-1 craze isn't close to being over.

In fact, 2026 is the year that we could see its evolution in pill form.

Danish drug maker Novo Nordisk kicked off the new year with the launch of its once-daily obesity pill Wegovy, named just like its injectable counterpart.

Because it's Wegovy, it sits on the back of all the safety data that Wegovy has been able Semaglutide has been able to create over the last ten years or so.

Novo's main competitor, Eli Lilly, has its own obesity pill that is waiting for FDA approval and that's expected within the next few months.

Obesity pills are the next battleground for these two drug makers, which are largely credited with establishing the booming GLP-1 industry.

In an analyst note published in 2025, Goldman Sachs analysts said that these pills could capture around a quarter of the global weight loss drug market by 2030,

which by then is expected to be valued at around $95 billion.

Up until now, the biggest holdout for some patients is the fact that GLP-1s are administered by an injection.

Pills could solve that problem and could also be a game-changer for patients who are seeking obesity treatment for the very first time.

I am very excited that no other phase three trials has been able to show this level [of] efficacy at 17% being equivalent to your injectable sister.

The cash price of Wegovy's pill will run patients between $150 to $300 per month, depending on the dose.

Still expensive for some patients, but slightly less than the cash price of the Wegovy injection.

The launch of the first GLP-1 obesity pill is a big deal for Novo Nordisk after a rough year and a half.

Eli Lilly stock on the other hand, has been on a tear.

In early 2025, the drug maker gained majority market share in the obesity and diabetes drug space for time.

First of all, Lilly's Zeppelin and Munjar are simply more effective than Novo's injections.

There's also increasing provider preference to prescribe Lilly's drugs.

Lastly, Lilly was quicker to launch direct to consumer efforts compared to Novo, which has allowed Lilly to scoop up more market share here.

At the same time, Novo has released data on its next generation obesity drugs that underwhelmed investors.

The company has also slashed its full year guidance several times and overall has had a hard time convincing Wall Street that it has more market moving drugs in its PIP pipeline.

Can its weight loss pill help turn things around?

Following the pill's approval, its stock price soared more than 10%.

While Nova and Lilly are farthest along, there are plenty of other players trying to take aim at this market.

Viking Therapeutics, AstraZeneca, and Pfizer, to name a few.

Injectables defined the last several years, but

2026 could be the year of the obesity pill.

Trying to solve the obesity crisis is far from over.